Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

Summary

GlobalData, the industry analysis specialist, has released its new report, “Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020”. The report is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provides comprehensive information on ovarian cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global ovarian cancer therapeutics market. It analyses the treatment usage patterns in the global ovarian cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global ovarian cancer sector. It quantifies the unmet need in the global ovarian cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. The ovarian cancer therapeutics market grew at a Compound Annual Growth Rate (CAGR) of only 1.0% between 2002 and 2011. The patent expiries of major branded products, such as Taxol (paclitaxel), Paraplatin (carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of generics, have acted as restraining factors to the market. The introduction of new and promising therapies such as Avastin (bevacizumab), AMG 386, EC145, Farletuzumab (MORAb-003), Karenitecin (BNP1350), OPAXIO (paclitaxel poliglumex), OPT-821, Paclical (paclitaxel), Vargatef (BIBF 1120) and Votrient (pazopanib) are expected to drive the market from 2011–2020. In 2011, the ovarian cancer therapeutics markets in key countries (the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were worth $736.7m collectively. The ovarian cancer therapeutics market is expected to witness three-fold growth by 2020, reaching $2,352m at a CAGR of 13.8%. This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to change the treatment paradigm of ovarian cancer when launched.

Scope

The scope of the report includes -

• An overview of ovarian cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized global ovarian cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data by stage of the disease from 2002 to 2010, forecast for 10 years to 2020.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
• Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
• Competitor assessment including drug launch analysis and drug sales forecasts.
• Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
• Analysis of unmet need in the market and target product profile including opportunity for target product.
• Technology trends analytic framework to assess strength of pipeline.
• Pipeline analysis data providing a split by stage of the disease and line of therapy across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include microtubule stabilizers, vascular endothelial growth factor receptor (VEGFR) inhibitors, immunomodulators, folate receptor inhibitors, poly ADP ribose polymerase (PARP) inhibitors, topoisomerase inhibitors, interleukins, mammalian target of rapamycin (mTOR) inhibitors and phosphatidylinositol-3-kinase (PI3K) inhibitors.
• Clinical trials mapping of trials for ovarian cancer in different regions.
• An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
• Analysis of the current and future market competition in the global ovarian cancer therapeutics market.
• Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Amgen Inc, AstraZeneca PLC, Boehringer Ingelheim GmbH, Oasmia Pharmaceutical AB, Endocyte, Inc, BioNumerik Pharmaceuticals, Inc, Eisai Inc., Cell Therapeutics, Inc, and Menarini Group,
• Analysis of licensing agreements during 2008-2010 in the ovarian cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
• Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
• Direct quotes from key opinion leaders (KOL) or physicians in the ovarian cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop business strategies and perform superior market quantification analysis by
• Understanding the trends shaping and driving the global ovarian cancer therapeutics market.
• Understanding treatment preferences of physicians in disease state and across treatment flow.
• Accessing market sizing, forecasts and quantified growth opportunities in the global ovarian cancer therapeutics market till 2020.
• Quantifying patient population in the global ovarian cancer market to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
• performing benchmarking analysis and growth opportunities against currently marketed products
• Identifying market entry points based on safety, efficacy, and pricing parameters.
• Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
• Develop and design your in-licensing and out-licensing strategies by
• Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
• Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
• Track drug sales in the global ovarian cancer therapeutics market from 2002 to 2020
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
• What’s the next big thing in the global ovarian cancer therapeutics market landscape? Identify, understand and capitalize.